Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Joy D. Fisher"'
Autor:
Michelle A. Rudek, David O. Kamson, Joy D. Fisher, William F. Elmquist, William Timmer, Benjamin M. Ellingson, Patrick Y. Wen, Carlos Romo, Jann N. Sarkaria, Xiaobu Ye, Ranjit S. Bindra, Stuart A. Grossman, L. Burt Nabors, Fred G. Barker, Jeffrey G. Supko, David M. Peereboom
Publikováno v:
Neuro-oncology, vol 22, iss 10
Neuro Oncol
Neuro Oncol
Author(s): Grossman, Stuart A; Romo, Carlos G; Rudek, Michelle A; Supko, Jeffrey; Fisher, Joy; Nabors, L Burt; Wen, Patrick Y; Peereboom, David M; Ellingson, Benjamin M; Elmquist, William; Barker, Fred G; Kamson, David; Sarkaria, Jann N; Timmer, Will
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c33b8d4ee97ca05be981c33976a5ae96
https://escholarship.org/uc/item/00t4v9f5
https://escholarship.org/uc/item/00t4v9f5
Autor:
Roy E. Strowd, Serena Desideri, Ichiro Nakano, L. Burt Nabors, Mina Lobbous, Jeffrey G. Supko, Joy D. Fisher, Tobias Walbert, Xiaobu Ye, Stuart A. Grossman, Neeraja Danda
Publikováno v:
Neuro-Oncology. 23:vi60-vi60
BACKGROUND Glioblastoma often can relapse as mesenchymal (MES) tumors, indicating a phenotypic shift during clinical progression. Glioma spheres, when they gain MES phenotypes, develop dependence on AXL for their growth both in vitro and in vivo. The
Autor:
Frank S. Lieberman, Joy D. Fisher, Byran Ozer, L. Burt Nabors, Patrick Y. Wen, David Schiff, Antonio Omuro, Serena Desideri, Jing Li, Benjamin M. Ellingson, Ranjit S. Bindra, Jian Campian, Stuart A. Grossman, Tobias Walbert, Arati Desai, Xiaobu Ye
Publikováno v:
Neuro-Oncology. 23:vi63-vi63
BACKGROUND Preclinical studies have demonstrated that IDH1-mutant (IDHmt) gliomas harbor a BRCAness phenotype with a defect in homologous recombination that confers PARP inhibitor sensitivity. Pamiparib (BeiGene BGB-290) is an effective PARP-trapping
Autor:
Patrick Y. Wen, Susan M. Chang, Alfred Yung, Tracy T. Batchelor, Stuart A. Grossman, Lakshmi Nayak, Alice P. Chen, Timothy F. Cloughesy, Frank S. Lieberman, Antonio Omuro, Xiaobu Ye, Joy D. Fisher, Mark R. Gilbert, Lisa M. DeAngelis, Jeffrey S. Wefel, Jan Drappatz, Michael D. Prados, John de Groot, Kenneth Aldape
Publikováno v:
Journal of neuro-oncology, vol 132, iss 1
Anti-vascular endothelial growth factor (VEGF) therapy has shown promise in the treatment of high-grade gliomas (HGG). Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for VEGF-A, VEGF-B and placental growth fac
Autor:
Manmeet S Ahluwalia, Patrick Y. Wen, Kellie N. Smith, Stuart A. Grossman, Jiajia Zhang, Joy D. Fisher, Michael Lim, Arati Desai, Tobias Walbert, Burt Nabors, John Choi, Anna F. Piotrowski, Serena Desideri, Christina Jackson, Drew M. Pardoll, Xiaobu Ye
Publikováno v:
Neuro Oncol
BACKGROUND Immune checkpoint inhibitors (ICIs) are not uniformly effective in glioblastoma treatment. Immunogenomic determinants may identify patients who are most likely to benefit from these therapies. Therefore, we compared the immunogenomic pheno
Autor:
Frank S. Lieberman, David Schiff, Asim K. Bag, Joy D. Fisher, Stuart A. Grossman, Glenn J. Lesser, Martin A. Lodge, L. Burt Nabors, Arati Desai, David A. Mankoff, Serena Desideri, Richard L. Wahl, Matthias Holdhoff, James M. Mountz, Akiva Mintz, Jeffrey P. Leal, Xiaobu Ye
Publikováno v:
Journal of Nuclear Medicine. 58:393-398
Quantitative 3'-deoxy-3'-18F-fluorothymidine (18F-FLT) PET has potential as a noninvasive tumor biomarker for the objective assessment of response to treatment. To guide interpretation of these quantitative data, we evaluated the repeatability of 18F
Autor:
Michelle Rudek-Renaut, Stuart A. Grossman, Joy D. Fisher, Patrick Y. Wen, Burt Nabors, Jeffrey G. Supko, Carlos G Romo, Xiaobu Ye, David M. Peereboom, Benjamin M. Ellingson
Publikováno v:
Neuro Oncol
Despite advances in the understanding of molecular pathways, the availability of NGS panels to identify potentially drugable mutations, the proliferation of targeted therapies, and the progress seen in other cancers, only one novel agent (temozolomid
Autor:
Stuart A. Grossman, Anna F. Piotrowski, Xiaobu Ye, Michael Lim, Burt Nabors, Patrick Y. Wen, Serena Desideri, Joy D. Fisher, Megan Sims
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78d833eb66a7fa6f773161001bb9e0cc
https://europepmc.org/articles/PMC5692042/
https://europepmc.org/articles/PMC5692042/
Autor:
Brian M. Alexander, Stuart A. Grossman, Megan Sims, Serena Desideri, Manmeet Ahluwalia, Jorg Dietrich, L. Burt Nabors, Jeffrey G. Supko, Keith L. Ligon, Nathalie Y. R. Agar, Xiaobu Ye, Joy D. Fisher, Thomas Kaley, Arati Desai, Patrick Y. Wen, Naoko Takebe, David M. Peereboom
Publikováno v:
Neuro-Oncology. 20:vi13-vi14
AZD1775 is an oral small molecular inhibitor of the G2/M checkpoint regulator Wee1. The Adult Brain Tumor Consortium 1202 trial (NCT01849146) is a phase I, open label, multicenter dose-finding study of AZD1775 in combination with standard RT and TMZ
Autor:
Serena Desideri, William L. Read, Stuart A. Grossman, Glenn J. Lesser, Arati Desai, Matthias Holdhoff, Louis B. Nabors, David Schiff, Frank S. Lieberman, Jeffrey G. Supko, Joy D. Fisher, Jeffrey P. Leal, Tobias Walbert, Martin A. Lodge, Xiaobu Ye, Richard L. Wahl
Publikováno v:
Neuro-oncology. 19(6)
Background Mibefradil (MIB), previously approved for treatment of hypertension, is a selective T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs). To exploit its presumed mechanism of impacting cell cycle activity (